GlobalNav-CamzyosUK

This promotional site is only intended for UK healthcare professionals.

This promotional site is only intended for UK healthcare professionals.

I am not a UK healthcare professional

Adverse Event Reporting

Prescribing Information
Menu
FAQs
Resources
image
image

CAMZYOS (mavacamten) maintenance dosing and treatment interruption guidance1

CAMZYOS treatment maintenance allows for regular assessment of treatment goals1

Maintenance and interruption


Treatment with CAMZYOS should be interrupted at any clinic visit if LVEF <50%1

Maintenance and interruption
horizontal Rule


LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow tract.

Reference
  1. CAMZYOS (mavacamten) Summary of Product Characteristics.

Adverse events should be reported. Reporting forms and information can be found at: UK - http://www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Bristol-Myers Squibb via
medical.information@bms.com or 0800 731 1736 (UK).

Legal Notice    |    Privacy Policy

© 2024 MyoKardia, Inc., a Bristol-Myers Squibb company. All rights reserved.

3500-GB-2300210 | February 2024